Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule

Cancer Cytopathology

Volumn 120, Issue 1, 2012, Pages 44-51

  Kang, Guhyun ^a   Cho, Eun Yoon ^a   Shin, Jung Hee ^a   Chung, Jae Hoon ^a   Kim, Jong Won ^a   Oh, Young Lyun ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

BRAF; Cytology; Fine needle aspiration; Papillary carcinoma; Thyroid

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE; BRAF PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; THYROID NODULE; THYROID PAPILLARY CARCINOMA; ADULT; CYTODIAGNOSIS; EVALUATION; FEMALE; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PATHOLOGY; THYROID TUMOR;

ADULT; BIOPSY, FINE-NEEDLE; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE;

EID: 84859826774     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20179     Document Type: Article

References (31)

1. Baloch Z, Layfield LJ. Quest for a uniform cyto-diagnostic approach to thyroid aspirates: a consensus proposal. Diagn Cytopathol. 2006;34:85-86.
2. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:425-437.
3. Grant CS, Hay ID, Gough IR, McCarthy PM, Goellner Jr. Long-term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. Surgery. 1989; 106:980-985; discussion 985-986.
4. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer. 2007;111: 306-315.
5. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111:508-516.
6. Chow LS, Gharib H, Goellner JR, van Heerden JA. Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas. Thyroid. 2001;11:1147-1151.
7. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180.
8. Tyler DS, Shaha AR, Udelsman RA, et al. Thyroid cancer: 1999 update. Ann Surg Oncol. 2000;7:376-398.
9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
10. Adeniran AJ, Zhu ZW, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
11. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003; 88:2318-2326.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
13. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373-6379.
14. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
15. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818-821.
16. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006;65:660-666.
17. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study. Radiology. 2008;247:762-770.
18. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin EndocrinolMetab. 2010;95:3693-3700.
19. Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011;96:658-664.
20. Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer Cytopathol. 2009;117:195-202.
21. Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med. 1993;13:699-709.
22. Wang HH. Reporting thyroid fine-needle aspiration: literature review and a proposal. Diagn Cytopathol. 2006;34:67-76.
23. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of ''follicular lesion of undetermined significance/atypia of undetermined significance''. Cancer Cytopathol. 2010;118:17-23.
24. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fineneedle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
25. Adeniran AJ, Theoharis C, Hui P, et al. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid. 2011 [Epub ahead of print].
26. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91: 3603-3610.
27. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer. 2007;96:16-20.
28. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742-762.
29. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
30. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27:2977-2982.
31. Melck AL, Yip L, Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010;15:1285-1293.